CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 356 enrolled
Drug / intervention
Sutent: observational studyother
Likely dose
Not stated in record
Key inclusion· 1
  • ✓Metastatic renal cell carcinoma patients receiving first-line treatment
Key exclusion· 1
  • ✕Any previous systemic therapy for renal cell carcinoma (except adjuvant treatment)

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00460798
NCT00460798N/ACompleted
CompareCT.gov

A Non-Interventional Study With SUTENT® In The First Line Treatment Of Renal Cell Cancer

Pfizer·observational·Posted Apr 16, 2007·Updated Nov 16, 2010

In Brief

An observational study evaluating Sutent: observational study for Renal Cell Carcinoma. Completed, enrolled 356 participants.

Detailed Summary

This non-interventional study includes patients with advanced and/or metastatic renal cell carcinoma who are treated with SUTENT and who did not receive any other systemic therapy before. The aim of the trial is to increase knowledge about quality of life, safety, efficacy and tolerability under conditions of routine use of Sutent. The individual observation period of each patient will be 1 year.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Cell Carcinoma
Countries--
Collaborators--

Timeline

N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 16, 2007
Enrollment StartFeb 1, 2007
Primary CompletionSep 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 19.2 years ago

Interventions

Sutent: observational studyother

SUNIKA - A Non-Interventional Study With SUTENT® In The First Line Treatment Of Renal Cell Carcinoma